{"name":"Respira Therapeutics","slug":"respira","ticker":"Private","exchange":"Private","domain":"respiratherapeutics.com","description":"Respira Therapeutics is a private company focused on respiratory and cannabinoid therapeutics. The company is developing innovative treatments for various respiratory diseases. With a strong pipeline of products, Respira Therapeutics is poised to make a significant impact in the market.","hq":"Toronto, Canada","founded":0,"employees":"","ceo":"Amir Sternhell","sector":"Respiratory / Cannabinoid Therapeutics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"RTA 408 patent cliff ($100M at risk)","drug":"RTA 408","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"deal","headline":"Respira Therapeutics Secures $50M in Series C Funding","summary":"Respira Therapeutics announced the completion of a $50 million Series C funding round, led by new investor Sofinnova Partners.","drugName":"","sentiment":"positive"},{"date":"2023-09-12","type":"trial","headline":"Respira Therapeutics Presents Positive Interim Data from Phase 2 Trial of RTA 408","summary":"Respira Therapeutics presented interim data from its Phase 2 trial of RTA 408, a cannabinoid-based treatment for idiopathic pulmonary fibrosis.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNaU44WW9KbTdheVhPYVF1V2xZOGlQTUFOU0xlaWZnMGZZMGxWZVNZRW4tZGw5TktWT2g4dG96UVdZZXlDc3Ytbi11LWtPb0lEVG1qV3NSc0JSRm1kemt3bWtRLXhyM01YSTk4cWs3dm5neEZEU09jQlBRLU9NaWxLUUpBOGwxVnE4OTRVaS1jMkJpZmZnc1hubUpScWtqbUdUTEg1WE95SUl1ODhzUHc?oc=5","date":"2025-12-30","type":"patent","source":"The Pharma Letter","summary":"Pharma M&A round-up 2025: protecting against patent cliffs to come - The Pharma Letter","headline":"Pharma M&A round-up 2025: protecting against patent cliffs to come","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxNS2toYUlteGtydXJCZTh6V042aGVWZ2sxeDBEbXdVYXBDTzZrOEljckhEZ2ZiUEpnbEVKUDNCYWozZnNheDlIa3JMd0ZScHhJQjVvNGtQNjhLNWlfQlhIdGY3eXYxX2paa0Uydk1ibE1TMUJXZkJxTk0takF6MUNtMVpHUy0yY3FQTUVGYVBoUTRYOTNhem50VnNlNTNickd4cmdUZ1I1aGNOaWtfLXhXLURrekpBc1FYMmIyN2pIajg3cjdjY2gzZmhKZjlsVjZ3UGtSdm1xem5NNVhJTFJ6MXU5MmR3bWt5eUltc3o5QVFkY0s2UFVwSFl6VzdYd2VGbjc4V3k2RGlza2dSaTdBT2dKbFcxTUVRcG9MWndB?oc=5","date":"2025-09-25","type":"deal","source":"PR Newswire","summary":"Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital - PR Newswire","headline":"Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPYUViYXNFdU5MZ2JjM2x2ckczQXJzbHYzamNzNFpQSEhlTjlEd1hPVWpEZWpWNFczTW9KWFFQTkxsY2tGN1dTYjlxeG5JOEFXVW9IMUExU1hYTlpTY2RpZXRWY0pleDdDRnF4WS1zLWhILVFFVnFYRlozR3paMDBOSU82YzFjNUxldWMwUmdWTFlZZml0OGtCV2NDbXpWdDFzVXloZy10cm9qVnBPWm5GMmM2clQwRmtjbG1Qa2VhelBTcE5zS2ZodW0tUFRrNjgzVUlQdEgzZEFvV1A3cDdkSF9YY3FsdHZvYm1VUy1n?oc=5","date":"2017-04-12","type":"deal","source":"PR Newswire","summary":"Respira Therapeutics Announces Collaboration with United Therapeutics to Treat Pulmonary Hypertension - PR Newswire","headline":"Respira Therapeutics Announces Collaboration with United Therapeutics to Treat Pulmonary Hypertension","sentiment":"neutral"}],"patents":[{"drugName":"RTA 408","drugSlug":"cannabinoid-based-treatment","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["United Therapeutics","Gilead Sciences","Biogen"],"therapeuticFocus":["Respiratory diseases","Cannabinoid therapeutics"],"financials":null,"yahoo":null}